BioMarin and n-Lorem Partner to Target Rare ReNU Syndrome

The partnership targets the RNU4-2 gene variant, a mutation estimated to drive approximately 75% of ReNU syndrome cases. While n-Lorem typically focuses on conditions affecting fewer than 30 people worldwide, the projected global population of 100,000 for this syndrome necessitated a larger-scale development approach. BioMarin will leverage its expertise in genetic medicine to lead the clinical advancement of the therapy, while both organizations will jointly conduct initial preclinical studies to select a lead candidate.

ReNU syndrome, characterized by significant cognitive and language impairments, currently lacks any FDA-approved treatments. The condition was first discovered by an international research team led by Dr. Nicola Whiffin at the University of Oxford and Dr. Ernest Turro at the Mt. Sinai Icahn School of Medicine. By combining n-Lorem’s rapid antisense technology with BioMarin's commercial and clinical infrastructure, the companies aim to provide a viable therapeutic pathway for a community that has historically lacked options.